(Reuters) - Barr said it was the first to file an application, containing a paragraph IV certification, to sell a generic version of the drug.
On July 20, Schering and the patent owner, Cancer Research Technology, had filed a suit in a U.S. federal court to prevent Barr from proceeding with the commercialization of its product.
Read more at Reuters.com Government Filings News
On July 20, Schering and the patent owner, Cancer Research Technology, had filed a suit in a U.S. federal court to prevent Barr from proceeding with the commercialization of its product.
Read more at Reuters.com Government Filings News
No comments:
Post a Comment